DOCSLIB.ORG

Gemfibrozil (Lopid)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gemfibrozil (Lopid) What is most important to remember? If you have questions: Strong Internal Medicine • Use this medicine as directed by your doctor Ask your doctor, nurse or pharmacist for more information about gemfibrozil (Lopid®) • It is important to continue taking this medicine even if you feel normal. Most people with high cholesterol or triglycerides do not feel sick • Do not start any new medicines, over-the-counter drugs or herbal remedies without talking to your doctor • Tell all doctors, dentists and pharmacists that you are using Strong Internal Medicine gemfibrozil (Lopid®) 601 Elmwood Avenue th • Contact your doctor right away if Ambulatory Care Facility, 5 Floor Rochester, NY 14642 you have severe muscle pain or Phone: (585) 275 -7424 weakness Gemfibrozil Visit our website at: (Lopid®): • Follow the diet and lifestyle www.urmc.rochester.edu/medicine/ - genera medicine/patientcare/ Important Patient Information changes that you talked about l- with your doctor in addition to taking your medicine to get the greatest health benefits What does gemfibrozil (Lopid®) do? Who should know I am taking gemfibrozil What are some things that I need to be aware • It is used to lower the level of bad cholesterol (Lopid®)? of when taking gemfibrozil (Lopid®)? (LDL), raise the level of good cholesterol Keep a list of all your medicines (prescription, • Tell your doctor or pharmacist if you are (HDL), and lower triglycerides (TG) in the natural products, supplements, vitamins, over- allergic to gemfibrozil, or if you are allergic to body the-counter) and give it to your healthcare any other medicines, foods, or substances provider (doctor, nurse, nurse practitioner, • It is also used to stop irritation of the • Tell your doctor if you have gallbladder pancreas pharmacist, or physician assistant) disease, kidney disease, or liver disease How should gemfibrozil (Lopid®) be used? Are there any interactions with other drugs before taking this medicine that I need to worry about? • Use this medicine as directed by your doctor • Tell your doctor if you are taking the medicine • There are many drug interactions that may repaglinide (Prandin®) to treat diabetes or a • This medicine is taken two (2) times a day. increase your risk of side effects “statin” such as simvastatin to treat high Take this medicine 30 minutes before cholesterol before taking this medication breakfast and dinner • Do not start new prescription, over-the- counter medicines, or herbal and dietary • If you take cholestyramine or colestipol, take • To gain the most benefit, do not miss doses supplements without telling your doctor gemfibrozil at least 1 hour before or 4-6 What should I do if I forget a dose? What side effects could occur with hours after taking these medicines. These • Take a missed dose as soon as you think gemfibrozil (Lopid®)? products can lower the absorption of gemfibrozil about it • Heartburn • If you are taking a blood thinner, you may • If it is close to the time for your next dose, • Loose stools (diarrhea) need to have your blood work checked more skip the missed dose and go back to your normal dose time frequently while taking this medicine. Talk with your doctor • Do not take 2 doses at the same time or extra doses • Tell your doctor if you are pregnant, plan to become pregnant during treatment, or if you If you have any of the following side effects, call your doctor or visit the emergency room are breastfeeding. You will need to talk with immediately: your doctor about the benefits and risks of this medicine while pregnant or breastfeeding • Very bad belly pain, upset stomach, • Dark urine or throwing up • Any sign of a severe allergic reaction • Avoid alcohol consumption (includes wine, • Muscle pain, weakness, or joint pain including: itching; rash; severe beer, and liquor) • Blurred eyesight dizziness; trouble breathing; swelling • Store in a cool, dry place. Protect from light of face, lips, tongue or throat and do not store in the bathroom • Severe headache • Depressed mood • Keep away from children and pets • Burning numbness or tingling feelings • Any bruising or bleeding • Very bad dizziness or passing out • Yellowing of the skin and eyes • Not normal heartbeat .
Load more

Recommended publications
  • Is Alcohol Use Related to High Cholesterol in Premenopausal
    Research iMedPub Journals Journal of Preventive Medicine 2018 http://www.imedpub.com/ Vol.3 No.1:3 ISSN 2572-5483 DOI: 10.21767/2572-5483.100024 Is Alcohol Use Related To High Cholesterol in Premenopausal Women Aged 40-51 Years Old? Sydnee Homeyer, Jessica L Hartos*, Holli Lueg, Jessica Moore and Patricia Stafford Department of Physician Assistant Studies, University of North Texas Health Science Center, USA *Corresponding author: Jessica L. Hartos, Department of Physician Assistant Studies, University of North Texas Health Science Center, USA, Tel: 817-735-2454; Fax: 817-735-2529; E-mail: [email protected] Received date: November 13, 2017; Accepted date: January 8, 2018; Publication date: January 15, 2018 Citation: Homeyer S, Hartos JL, Lueg H, Moore J, Stafford P, et al. (2018) Is Alcohol Use Related To High Cholesterol In Premenopausal Women Aged 40-51 Years Old? J Prev Med Vol.3 No.3: 3. Copyright: © 2018 Homeyer S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. Introduction Abstract Increased serum cholesterol levels is a major risk factor for coronary heart disease (CHD) [1], and over seventy-one million Purpose: Alcohol use and cholesterol are related in men and American adults have high cholesterol (27%) [2,3]. In American postmenopausal women but relations between alcohol use women, cholesterol levels have been shown to increase with and cholesterol are unclear for premenopausal women. The age, and nearly 1 in 2 American women has high or borderline purpose of this study was to determine whether alcohol use was related to cholesterol in women aged 40-51 years old.
    [Show full text]
  • E the Effect of Topiramate on Weight Loss in Patients with Type 2 Diabetes
    E The effect of topiramate on weight loss in patients with type 2 diabetes RTICL Sedighe Moradi, Scott Reza Jafarian Kerman, Mina Mollabashi A Institute of Endocrinology and Metabolism (Hemmat Campus), Firoozgar Hospital, Tehran University of Medical Sciences, Tehran, Iran Background: Obesity has been associated with several co‑morbidities such as diabetes and increased mortality. In general, the use of medication promotes only a modest weight loss in the range of 2 to 10 kg, usually most effective during the first 6 months of therapy; however, studies have shown positive effects on other risk factors such as blood pressure and serum glucose levels, but there are fewer studies in patients with diabetes. The aim of this study was to assess the effect of topiramate on weight reduction patients with type 2 diabetes. Materials and Methods: This was a 32‑week randomized clinical trial study of 69 subjects during 2008‑2010. RIGINAL Patients, in two treatment groups were given topiramate (39 patients) and Placebo (30 patients) and were subjected to participation in a non‑pharmacologic lifestyle intervention program; which were randomly allocated in our two groups. The percentage change in body O weight and Body Mass Index (BMI) at the end of the study was the primary efficacy endpoint and secondary indicators were changes in blood pressure (BP), proportion of subjects who achieved 5% or 10% weight loss, changes in lipid profile (total cholesterol, low‑density lipoprotein cholesterol, high‑density lipoprotein cholesterol, triglycerides); and changes in glycosylated hemoglobin (HgA1c). Paired samples and independent samples t‑test was used for statistical analysis.
    [Show full text]
  • Kava Kava Extract Is Available from Ashland Chemical Co., Mini Star International, Inc., and QBI (Quality Botanical Ingredients, Inc.)
    SUMMARY OF DATA FOR CHEMICAL SELECTION Kava Kava 9000-38-8; 84696-40-2 November 1998 TABLE OF CONTENTS Basis for Nomination Chemical Identification Production Information Use Pattern Human Exposure Regulatory Status Evidence for Possible Carcinogenic Activity Human Data Animal Data Metabolism Other Biological Effects Structure-Activity Relationships References BASIS OF NOMINATION TO THE CSWG Kava kava is brought to the attention of the CSWG because it is a rapidly growing, highly used dietary supplement introduced into the mainstream U.S. market relatively recently. Through this use, millions of consumers using antianxiety preparations are potentially exposed to kava kava. A traditional beverage of various Pacific Basin countries, kava clearly has psychoactive properties. The effects of its long-term consumption have not been documented adequately; preliminary studies suggest possibly serious organ system effects. The potential carcinogenicity of kava and its principal constituents are unknown. INPUT FROM GOVERNMENT AGENCIES/INDUSTRY The U.S. Pharmacopeia is in the process of reviewing kava kava. No decision on preparation of a monograph has been made. SELECTION STATUS ACTION BY CSWG: 12/14/98 Studies requested: - Toxicological evaluation, to include studies of reproductive toxicity and neurotoxicity - Genotoxicity Priority: High Rationale/Remarks: - Significant human exposure - Leading dietary supplement with rapidly growing use - Concern that kava has been promoted as a substitute for ritilin in children - Test extract standardized to 30 percent kavalactones - NCI is conducting studies in Salmonella typhimurium CHEMICAL IDENTIFICATION CAS Registry Number: 9000-38-8 Kava-kava resin (8CI) Chemical Abstract Service Name: 84696-40-2 CAS Registry Number: Pepper (Piper), P. methysticum, ext. Chemical Abstract Service Name: Extract of kava; kava extract; Piper Synonyms and Trade Names: methisticum extract Description: The tropical shrub Piper methysticum is widely cultivated in the South Pacific.
    [Show full text]
  • Statin-Induced Myopathy: Translational Studies from Preclinical to Clinical Evidence
    International Journal of Molecular Sciences Review Statin-Induced Myopathy: Translational Studies from Preclinical to Clinical Evidence Giulia Maria Camerino 1, Nancy Tarantino 1 , Ileana Canfora 1 , Michela De Bellis 1, Olimpia Musumeci 2 and Sabata Pierno 1,* 1 Section of Pharmacology, Department of Pharmacy and Drug Sciences, University of Bari “Aldo Moro”, 70125 Bari, Italy; [email protected] (G.M.C.); [email protected] (N.T.); [email protected] (I.C.); [email protected] (M.D.B.) 2 Unit of Neurology and Neuromuscular Disorders, Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy; [email protected] * Correspondence: [email protected] Abstract: Statins are the most prescribed and effective drugs to treat cardiovascular diseases (CVD). Nevertheless, these drugs can be responsible for skeletal muscle toxicity which leads to reduced compliance. The discontinuation of therapy increases the incidence of CVD. Thus, it is essential to assess the risk. In fact, many studies have been performed at preclinical and clinical level to investigate pathophysiological mechanisms and clinical implications of statin myotoxicity. Conse- quently, new toxicological aspects and new biomarkers have arisen. Indeed, these drugs may affect gene transcription and ion transport and contribute to muscle function impairment. Identifying a marker of toxicity is important to prevent or to cure statin induced myopathy while assuring the right therapy for hypercholesterolemia and counteracting CVD. In this review we focused on the mechanisms of muscle damage discovered in preclinical and clinical studies and highlighted the Citation: Camerino, G.M.; Tarantino, pathological situations in which statin therapy should be avoided.
    [Show full text]
  • Tegretol (Carbamazepine)
    Page 3 Tegretol® carbamazepine USP Chewable Tablets of 100 mg - red-speckled, pink Tablets of 200 mg – pink Suspension of 100 mg/5 mL Tegretol®-XR (carbamazepine extended-release tablets) 100 mg, 200 mg, 400 mg Rx only Prescribing Information WARNING SERIOUS DERMATOLOGIC REACTIONS AND HLA-B*1502 ALLELE SERIOUS AND SOMETIMES FATAL DERMATOLOGIC REACTIONS, INCLUDING TOXIC EPIDERMAL NECROLYSIS (TEN) AND STEVENS-JOHNSON SYNDROME (SJS), HAVE BEEN REPORTED DURING TREATMENT WITH TEGRETOL. THESE REACTIONS ARE ESTIMATED TO OCCUR IN 1 TO 6 PER 10,000 NEW USERS IN COUNTRIES WITH MAINLY CAUCASIAN POPULATIONS, BUT THE RISK IN SOME ASIAN COUNTRIES IS ESTIMATED TO BE ABOUT 10 TIMES HIGHER. STUDIES IN PATIENTS OF CHINESE ANCESTRY HAVE FOUND A STRONG ASSOCIATION BETWEEN THE RISK OF DEVELOPING SJS/TEN AND THE PRESENCE OF HLA-B*1502, AN INHERITED ALLELIC VARIANT OF THE HLA-B GENE. HLA-B*1502 IS FOUND ALMOST EXCLUSIVELY IN PATIENTS WITH ANCESTRY ACROSS BROAD AREAS OF ASIA. PATIENTS WITH ANCESTRY IN GENETICALLY AT- RISK POPULATIONS SHOULD BE SCREENED FOR THE PRESENCE OF HLA-B*1502 PRIOR TO INITIATING TREATMENT WITH TEGRETOL. PATIENTS TESTING POSITIVE FOR THE ALLELE SHOULD NOT BE TREATED WITH TEGRETOL UNLESS THE BENEFIT CLEARLY OUTWEIGHS THE RISK (SEE WARNINGS AND PRECAUTIONS/LABORATORY TESTS). APLASTIC ANEMIA AND AGRANULOCYTOSIS APLASTIC ANEMIA AND AGRANULOCYTOSIS HAVE BEEN REPORTED IN ASSOCIATION WITH THE USE OF TEGRETOL. DATA FROM A POPULATION-BASED CASE CONTROL STUDY DEMONSTRATE THAT THE RISK OF DEVELOPING THESE REACTIONS IS 5-8 TIMES GREATER THAN IN THE GENERAL POPULATION. HOWEVER, THE OVERALL RISK OF THESE REACTIONS IN THE UNTREATED GENERAL POPULATION IS LOW, APPROXIMATELY SIX PATIENTS PER ONE MILLION POPULATION PER YEAR FOR AGRANULOCYTOSIS AND TWO PATIENTS PER ONE MILLION POPULATION PER YEAR FOR APLASTIC ANEMIA.
    [Show full text]
  • Alcohol and the Cardiovascular System
    Alcohol and the Cardiovascular System Molecular Mechanisms for Beneficial and Harmful Action SAM ZAKHARI, PH.D. Alcohol can be beneficial or harmful to the cardiovascular system, depending on the amount consumed and the characteristics of the consumer. Of the numerous cellular and molecular mechanisms that are thought to explain the beneficial effects of moderate drinking, this article discusses four, involving (1) high density lipoproteins, (2) cellular signaling, (3) platelet function in blood clot formation, and (4) stimulation of blood clot dissolution. Although light-to-moderate drinking can protect against coronary artery disease, heavy alcohol consumption can damage the cardiovascular system, resulting in maladies such as heart muscle disorders, irregular heart rhythms, high blood pressure, and strokes. This article summarizes representative epidemiological and animal studies on these cardiovascular consequences of chronic heavy alcohol consumption and reviews mechanisms that have been suggested to explain alcohol’s effects. KEY WORDS: chronic AODE (alcohol and other drug effects); molecular interaction; biochemical mechanism; lipoproteins; platelets; blood coagulation; moderate AOD use; heavy AOD use; therapeutic drug effect; AODR (alcohol and other drug related) disorder; alcoholic cardiomyopathy; cardiac arrhythmia; hypertensive disorder; stroke; literature review; cell signaling lcoholic beverages have been sumed. This chronic heavy drinking1 is used—and abused—since the 1The term “heavy drinking” is not used consistently in a significant factor in the development the alcohol literature; therefore, this article generally dawn of history. Although most 2 A of alcohol dependence, or alcoholism, refers to “heavy drinking” and “heavy drinkers” based people who choose to drink can limit their and is associated with serious adverse on the terms used in the reference cited.
    [Show full text]
  • Analytical Studies on the Kavain Metabolism in Human Specimen and Liver Cell Lines
    Analytical studies on the kavain metabolism in human specimen and liver cell lines Inaugural-Dissertation zur Erlangung des Doktorgrades der Mathematisch-Naturwissenschaftlichen Fakultät der Heinrich-Heine-Universität Düsseldorf Vorgelegt von Fuad Ali Tarbah aus Derna, Libyen Düsseldorf 2003 Gedruckt mit Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät der Heinrich-Heine-Universität Düsseldorf Referent: Prof. Dr. Th. Daldrup Korreferent: Prof. Dr. G. Willuhn, Prof. Dr. H. Weber Tag der mündlichen Prüfung: 17. 12. 2003 Parts of this Ph.D. Thesis have already been presented and/or published in: Tarbah F. A., Mahler H., Temme O. and Daldrup Th. Mass spectral characterisation of hepatic cell metabolites of D,L-kavain using HPLC and GC/MS systems. Special issue: 37th TIAFT triennial meeting “Problems of Forensic Sciences” XLII: 173-180 (1999) Tarbah F. A., Mahler H., Temme O. and Daldrup Th. Determination of D,L-kavain and its metabolites in blood, serum and urine. Rapid quantitative method using fluid/fluid extraction and gas chromatography/mass spectrometry (GC/MS). Poster in 79. Jahrestagung der Deutschen Gesellschaft für Rechtsmedizin, Medizinische Einrichtungen der Universität / Gesamthochschule Essen (2000) Tarbah F., Mahler H., Kardel B., Weinmann W., Hafner D. and Daldrup Th. Kinetics of kavain and its metabolites after oral application. J. Chromatogr. B 789 (1): 115-130 (2003) Cabalion P., Barguil Y., Duhet D., Mandeau A., Warter S., Russmann S., Tarbah F. and Daldrup Th. Kava in modern therapeutic uses: to a better evaluation
    [Show full text]
  • A Brief Overview of Psychotropic Medication Use for Persons with Intellectual Disabilities
    A BRIEF OVERVIEW OF PSYCHOTROPIC MEDICATION USE FOR PERSONS WITH INTELLECTUAL DISABILITIES INTRODUCTION Individuals with intellectual disabilities are not uncommonly prescribed psychotropic medications. Too often, historically, such agents have been used to try to improve behavioral control without adequate understanding of the antecedents, purpose, and reinforcement of the problematic behavior. While an individual with an intellectual disability may experience a depressive, anxiety, or psychotic disorder in the more typical sense some individuals experience a pattern of anxiety/alarm/arousal leading to affective dysregulation and impulsive behavior. The anxiety can be stimulated by environmental change, physical discomfort, cues related to past trauma, overstimulation, boredom, confusion, or other unpleasant states. Addressing what is causing the distress or reinforcing the behavioral response is the most important thing (though not always easy). Psychotropic medications may be useful for treating more typically presenting psychiatric illnesses as well as being part of more comprehensive plans to attenuate risk behaviors. An individual with intellectual disabilities who seems sad, is withdrawn, shows low energy and lack of interest, is eating or sleeping more or less, or may be more irritable could be suffering from a depression that needs medication treatment. On the other hand an individual with intellectual disabilities who demonstrates aggression, property destruction, self-injury, or other forms of “dyscontrol” may be helped by medication aimed at blunting the anxiety/alarm and/or blocking its escalation into aggression or other dangerous behaviors. In such instances the medications are just part of an overall strategy or plan to help the individual avoid the “need” to engage in such behavior.
    [Show full text]
  • A Study of the Transduction Current of Vertebrate
    A STUDY OF THE TRANSDUCTION CURRENT OF VERTEBRATE OLFACTORY NEURONS By Chih-Chun LIN A dissertation submitted to Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland June, 2015 © 2015 Chih-Chun LIN All Rights Reserved Abstract Vertebrate olfactory transduction is a G-protein-coupled receptor pathway that involves the sequential activation of two ion channels to generate an electric signal in the olfactory receptor neurons (ORNs). The opening of one of these, the CNG channel, leads to Ca2+ influx, which then activates a calcium-activated Cl channel, Ano2 (anoctamin2 or TMEM16B). Because the chloride concentration in ORNs is constitutively high, the opening of Ano2 results in a Cl efflux, hence an inward current. Thus, the Cl current is believed to amplify the signal from the CNG channel. The CNG current in ORNs is subject to Ca2+-mediated adaptation, but it is difficult to study this question in detail because the presence of the Cl current typically masks a good part of the CNG current. To understand the interaction between the CNG and Cl currents via the Ca2+ influx, we have succeeded in developing a method to dissect the transduction current into its CNG and Cl components, thus revealing the kinetics of each. In addition, we characterized an Ano2-/- mouse line as the platform for further study of CNG current in the future. ii TABLE OF CONTENTS Abstract…………………………………………………………………………………...ii TABLE OF CONTENTS………………………………………………………………...iii TABLE OF FIGURES AND TABLES…………………………………………………..v ACKNOWLEDGEMENTS……………………………………………………………..vii Chapter 1 Introduction…………………………………………………………………...1 1.1 Gross anatomy of olfactory system……………………………………………….1 1.2 Histology of the olfactory epithelium…………………………………………….
    [Show full text]
  • Bempedoic Acid and Inclisiran for Patients with Heterozygous Familial Hypercholesterolemia and for Secondary Prevention of ASCVD: Effectiveness and Value
    Bempedoic Acid and Inclisiran for Patients with Heterozygous Familial Hypercholesterolemia and for Secondary Prevention of ASCVD: Effectiveness and Value Draft Evidence Report November 12, 2020 Prepared for ©Institute for Clinical and Economic Review, 2020 ICER Staff and Consultants Modeling Team Grace A. Lin, MD, MAS Dhruv S. Kazi, MD, MSc, MS Associate Professor of Medicine and Health Policy Associate Director, Smith Center for Outcomes University of California, San Francisco Research in Cardiology Director, Cardiac Critical Care Unit Jane Jih, MD, MPH Beth Israel Deaconess Medical Center Assistant Professor, Division of General Internal Associate Professor, Harvard Medical School Medicine University of California, San Francisco Foluso Agboola, MBBS, MPH Director, Evidence Synthesis Dr. Kazi was responsible for the development of the ICER cost-effectiveness model, interpretation of results, and drafting of the economic sections of this report; the Rick Chapman, PhD, MS resulting ICER reports do not necessarily represent the Director of Health Economics views of Beth Israel Deaconess Medical Center or ICER Harvard Medical School. Steven D. Pearson, MD, MSc President ICER DATE OF PUBLICATION: November 12, 2020 How to cite this document: Lin GA, Kazi DS, Jih J, Agboola F, Chapman R, Pearson SD. Inclisiran and Bempedoic Acid for Patients with Heterozygous Familial Hypercholesterolemia and for Secondary Prevention of ASCVD: Effectiveness and Value; Draft Evidence Report. Institute for Clinical and Economic Review, November 12, 2020. https://icer-review.org/material/high-cholesterol-update- draft-evidence-report/ Grace Lin served as the lead author for the report and wrote the background, other benefits, and contextual considerations sections of the report, with Jane Jih serving as a co-author.
    [Show full text]
  • PI Changes for Fibrates
    Changes to Product Information as approved by the CHMP on 21 October 2010, pending endorsement by the European Commission 1 BEZAFIBRATE ANNEX I -SUMMARY OF PRODUCT CHARACTERISTICS 4.1 Therapeutic indications (to replace current text) [Product name] is indicated as an adjunct to diet and other non-pharmacological treatment (e.g. exercise, weight reduction) for the following: - Treatment of severe hypertriglyceridaemia with or without low HDL cholesterol. - Mixed hyperlipidaemia when a statin is contraindicated or not tolerated. 5.1 Pharmacodynamic properties (Additional text) There is evidence that treatment with fibrates may reduce coronary heart disease events but they have not been shown to decrease all cause mortality in the primary or secondary prevention of cardiovascular disease ANNEX III -LABELLING AND PACKAGE LEAFLET What [Product name] is and what it is used for [Product name] belongs to a group of medicines, commonly known as fibrates. These medicines are used to lower the level of fats (lipids) in the blood. For example the fats known as triglycerides. [Product name] is used, alongside a low fat diet and other non-medical treatments such as exercise and weight loss, to lower levels of fats in the blood. 2 CIPROFIBRATE ANNEX I -SUMMARY OF PRODUCT CHARACTERISTICS 4.1 Therapeutic indications (to replace current text) [Product name] is indicated as an adjunct to diet and other non-pharmacological treatment (e.g. exercise, weight reduction) for the following: - Treatment of severe hypertriglyceridaemia with or without low HDL cholesterol. - Mixed hyperlipidaemia when a statin is contraindicated or not tolerated. 5.1 Pharmacodynamic properties (Additional text) There is evidence that treatment with fibrates may reduce coronary heart disease events but they have not been shown to decrease all cause mortality in the primary or secondary prevention of cardiovascular disease ANNEX III -LABELLING AND PACKAGE LEAFLET What [Product name] is and what it is used for [Product name] belongs to a group of medicines, commonly known as fibrates.
    [Show full text]
  • Fenofibrate, Bezafibrate, Ciprofibrate and Gemfibrozil Procedure Number
    28 February 2011 EMA/CHMP/580013/2012 Assessment report for fenofibrate, bezafibrate, ciprofibrate, and gemfibrozil containing medicinal products pursuant to Article 31 of Directive 2001/83/EC, as amended INN: fenofibrate, bezafibrate, ciprofibrate and gemfibrozil Procedure number: EMEA/H/A-1238 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7051 E -mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 3 1.1. Referral of the matter to the CHMP ......................................................................... 3 2. Scientific discussion ................................................................................ 3 2.1. Introduction......................................................................................................... 3 2.2. Clinical aspects .................................................................................................... 4 2.2.1. PhVWP recommendation ..................................................................................... 4 2.2.2. CHMP review ..................................................................................................... 7 2.2.3. Discussion .....................................................................................................
    [Show full text]